Firefly Neuroscience, Inc. (AIFF) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Firefly Neuroscience, Inc. is a Delaware corporation developing medical devices and AI-driven technology for high-resolution visualization of neuro-physiological interconnections. The company operates under a single reportable segment, "Firefly Products," and trades on the Nasdaq Capital Market. Following the acquisition of Evoke Neuroscience, Inc. in April 2025, the company has expanded its product portfolio to include the Evoke System, deployed across more than 85 clinical sites in the U.S.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $485 | $43 |
| Gross Profit | $221 | $43 |
| Gross Margin | 45.6% | 100.0% |
| Operating Loss | $(2,010) | $(2,065) |
| Net Loss | $(2,004) | $(12,930) |
| Cash and Cash Equivalents (End of Period) | $3,127 | $9,545 |
| Net Cash Used in Operating Activities | $(1,948) | $(2,511) |
| Net Cash Provided by Financing Activities | $2,386 | $10,253 |
| Total Assets | $10,910 | $10,477 |
| Total Liabilities | $2,468 | $2,840 |
| Accumulated Deficit | $(113,619) | $(104,424) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by $442,000 (1,028%) to $485,000, primarily driven by the inclusion of Evoke Neuroscience operations following the April 2025 acquisition. Revenue streams now include subscriptions ($161k), services ($216k), and product sales ($87k).
- Cost of Goods Sold (COGS): COGS emerged at $264,000 compared to $0 in the prior year, reflecting material and personnel costs associated with the Evoke product line. This reduced the gross margin to 45.6% from 100% in Q1 2025.
- Operating Expenses: Total operating expenses increased slightly to $2,231,000 from $2,108,000. Research and Development (R&D) expenses rose 36% to $424,000 due to product development spending. Conversely, Selling and Marketing expenses decreased 32% to $141,000 due to headcount reductions and fewer consultants.
- Net Loss Improvement: Net loss narrowed significantly to $(2,004,000) from $(12,930,000). The prior year's loss was heavily impacted by a $9,369,000 loss on the change in derivative fair value and a $1,353,000 loss on the settlement of a convertible promissory note, neither of which occurred in Q1 2026.
- Liquidity: Cash balances increased by $380,000 during the quarter to $3,127,000, supported by financing activities. However, the company continues to burn cash from operations.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern due to an accumulated deficit of $113.6 million and recurring negative cash flows. Management's plan relies on disciplined expense management and continued access to capital markets.
- Capital Raising:
- Q1 2026: Raised $2.386 million via a private placement of units and warrant exercises.
- Subsequent Events: On April 16, 2026, the company raised an additional $8.0 million in a subsequent closing of the same private placement. On May 6, 2026, it entered an agreement for up to $1.0 million in additional proceeds (pending shareholder approval).
- ATM Program: An At-The-Market (ATM) offering program with up to $7.4 million capacity was established in February 2026, but no shares had been sold as of May 8, 2026.
- Internal Controls: Management concluded that internal controls over financial reporting were not effective as of March 31, 2026, citing material weaknesses in Information Technology General Controls (ITGCs) and a lack of segregation of duties. Remediation is expected to be completed in Q2 2026.
- Risks: Key risks include the need for additional funding to sustain operations, regulatory hurdles for AI/ML medical devices, and geopolitical risks related to operations in Israel.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $10.25 million raised in Q1 and subsequent closings against the current burn rate of approximately $2 million per quarter.
- Revenue Quality: Assess the sustainability of the revenue spike driven by the Evoke acquisition and the mix of recurring subscription revenue versus one-time product sales.
- Dilution Impact: Review the terms of the recent private placements (units with warrants at $1.88 and $2.50) and the potential dilution from the ATM program and outstanding warrants (approx. 3.9 million).
- Internal Control Remediation: Monitor the progress of the remediation plan for ITGC and segregation of duties weaknesses to ensure future financial reporting reliability.
- Regulatory Status: Confirm the FDA clearance status of the Evoke System and any pending regulatory actions regarding the AI/ML components of the platform.